NYSE · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Can-Fite BioPharma Ltd. CANF
8 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$405,000
▼ 39.9% vs FY2024
EPS · FY25
$-5.97
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-178.2%
Net margin · FY25
-2426.7%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 405,000.00
Revenue, FY2025 · full 8-year series below
Revenue
Net income
The company lost 2427 cents on every revenue dollar this year.
Per share
USD -5.97
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-178.2%
Return on equity, FY2025
ROE
Operating margin-2456.8%
Net margin-2426.7%
Return on assets-105.5%
Each USD of equity lost 178 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−11.9% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−20.6%
−11.9%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.00B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 9.5M
total assets, end of FY2025
Total assetsUSD 9.5M
EquityUSD 5.6M
CashUSD 5.5M
Current ratio3.46×
Equity funds 59% of total assets.
History
8 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
·
·
·
·
·
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−5.97
−10.86
−17.92
−0.01
−0.03
−0.04
−0.14
−0.17
Dividend / sh $
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
−21
−5
·
·
ROE %
−178.2
−134.9
−142.5
−107.9
−123.3
−339.2
−462.7
−219.1
Shares out B
0.00
0.00
1.36
0.82
0.82
0.46
0.12
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
22 of 22
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed